Merck announced positive results from two phase III trials of its oral PCSK9 inhibitor, enlicitide decanoate, demonstrating significant reductions in LDL cholesterol in patients on statins with high cholesterol risks. These successful outcomes mark a pivotal step toward commercializing the first oral PCSK9 drug, potentially transforming cholesterol management in a crowded therapeutic field.